Abstract:Abstract Background Evidence for central nervous system involvement in primary Sjögren’s syndrome (pSS) patients is controversial and extremely limited. We aimed to describe the clinical profiles and high-risk indicators of primary Sjögren’s syndrome (pSS) patients with central nervous system (CNS) involvement (pSS-CNS). Methods A total of 412 participants with pSS from a hospital in China from January 2012 to December 2019 were enrolled in the retrospective study. 42 pSS-CNS patients were compared with 370 pSS patients without CNS involvement. The clinical features, laboratory examinations, imaging characteristics, and treatment of the pSS-CNS cases were systematically analyzed. Potential risk factors related to pSS-CNS patients were identified by multivariate logistic regression analysis. Results The prevalence of central nervous system involvement in the studied pSS patients was 10.2% (42/412), with 31.3% (14/42) of pSS patients having neurological manifestations as the initial symptom. The manifestations of hemiparesis (35.7%, 15/42), paraparesis (28.6%, 12/42), dysphonia (31.0%, 13/42), blurred vision (21.4%, 9/42), and dysfunctional proprioception (23.8%, 10/42) were more common in the pSS-CNS patients. Cerebral infarction (57.1%, 24/42), demyelination (31.0%, 13/42), myelitis (23.8%, 11/42), and angiostenosis (21.4%, 9/42) were most often found on MRI or CT scan imaging in the pSS-CNS patients. Intrathecal IgG level and total protein of cerebrospinal fluid were increased in 50% (8/16) of the pSS-CNS group. In comparison with patients without CNS involvement, the pSS-CNS patients were found to also have kidney and lung involvement, hematologic abnormalities, positive ANA and anti-SSA antibody tests, and reduced complement 3 (C3) and complement 4 (C4) levels (all p < 0.05). The prevalence of lung involvement, immune thrombocytopenia, and high-titer ANA (1:1000) were significantly higher in pSS-CNS disease activity compared to those in the moderately active group. Multivariate analysis identified lung involvement, anti-SSA positivity, and low C3 levels as prognostic factors for pSS-CNS. After high-dose glucocorticoids and immunosuppressive therapy, 60.5% (26/38) of pSS-CNS patients improved, 36.8% (14/38) were unresponsive to treatment, and 2.6% (1/38) died. Conclusion Clinical features are diverse in pSS-CNS patients, and the morbidity rate is low. CNS involvement was the initial presentation in state percentage here pSS patients. Pulmonary involvement, a positive anti-SSA antibody test, and reduced C3 levels are potential risk factors for CNS involvement in pSS. Treatment with high-dose glucocorticoids and immunosuppressive therapy appeared effective in 60% of pSS-CNS patients. Key Points • The CNS manifestations of pSS are diverse, and CNS imaging and CSF analysis are important for the diagnosis. • Pulmonary involvement, positive anti-SSA, and reduced C3 levels are potential risk factors of pSS-CNS. • About 60% of pSS-CNS patients were responsive to high-dose glucocorticoid administration and immunosuppressive therapy.

Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome

Central Nervous System Involvement in Primary Sjögren's Syndrome: a Study of 38 Patients

Clinical analysis of the neurological involvement in primary Sj(o)gren's syndrome

The Clinical Characteristics Of Primary Sjogren'S Syndrome With Neuromyelitis Optica Spectrum Disorder In China A Strobe-Compliant Article

Clinical stratification of 1318 Primary Sjögren's Syndrome patients

The Clinical Characteristics of Primary Sjogren's Syndrome with Neuromyelitis Optica Spectrum Disorder in China

Two Cases of Primary Sjögren's Syndrome with Neurological Impairment As Initial Symptom

Clinical features and risk factors of primary Sjögren’s syndrome complicated with severe pneumonia: a case–control study

Patients with Early-Onset Primary Sjögren’s Syndrome Have Distinctive Clinical Manifestations and Circulating Lymphocyte Profiles

Peripheral neuropathy in primary Sj(o)gren's syndrome

Childhood primary Sjogren syndrome with central nervous system symptoms as the first manifestation: a case report and literature review

[Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody]

Clinical features and risk factors for primary Sjögren’s syndrome combined with interstitial lung disease: a retrospective study

[Analysis of the Clinical Features at Onset of Primary Sjögren's Syndrome].

Clinical features and outcomes from the Singapore Sjögren's syndrome study

Clinical features of interstitial lung involvement in primary Sj(o)gren's syndrome

The clinical characteristics of 573 cases of primary Sj(o)gren's syndrome

Clinical features of newly-diagnosed primary Sj(o)gren's syndrome: analysis of 86 cases

Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: A case-control study.

Neuropsychiatric complications of 28 cases primary Sjgrens’syndrome.

Hypocomplementemia in Primary Sjogren's Syndrome: Association with Serological, Clinical Features, and Outcome.